vimarsana.com

Page 57 - ஹாங் காங் ஞானஸ்நானம் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hong Kong designs Spermine Risk Score for diagnosis of prostate cancer

Among the 905 patients recruited between 2015 and 2019 to participate in a study, 600 of them who had PSA levels ranging from 4 to 20 ng/mL were included in the analysis. Their urine samples were collected before they underwent a biopsy procedure. The biopsy results showed that out of the 600 patients, 185 (30.8 per cent) were diagnosed with prostate cancer

HKBU and CUHK launch Spermine Risk Score for prostate cancer diagnosis

Researchers from Hong Kong Baptist University (HKBU) and the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) have jointly developed the Spermine Risk Score which, coupled with the use of a urine test, provides a non-invasive and more reliable method for the diagnosis of prostate cancer. In a study conducted by the researchers, about 37% of the patients, who were ultimately found to have no prostate cancer, can avoid undergoing a prostate biopsy procedure.

Medical Alert Systems Market Worth USD 17 29 Billion by 2027 at 6 46% CAGR | Industry Growth Fueled as Key Players Focus on R&D Initiatives, Says Market Research Future (MRFR)

Medical Alert Systems Market Worth USD 17.29 Billion by 2027 at 6.46% CAGR | Industry Growth Fueled as Key Players Focus on R&D Initiatives, Says Market Research Future (MRFR) February 08, 2021 07:51 ET | Source: Market Research Future Market Research Future Medical Alert Systems Market Overview: The medical alert systems market is all set to witness robust growth due to the growing number of elderly individuals and mobile personal emergency management systems. The government s provision of social security benefits to the geriatric population, combined with independent living growth, has created a favorable climate for the global market. Thus, Market Research Future (MRFR) expects the Medical Alert Systems Market to record a CAGR of 6.46% over the review period (between 2017 and 2027) and estimated to reach USD 17.29 billion in 2027.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.